First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer

DOI PDF 2 Citations

Keunchil Park

Division of Haematology-Oncology, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea
Chong-Jen Yu

Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan
Sang-We Kim

Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea
Meng-Chih Lin

Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan 5Chang Gung University College of Medicine, Kaohsiung City, Taiwan
Virote Sriuranpong

Division of Medical Oncology, Chulalongkorn University, Bangkok, Thailand
Chun-Ming Tsai

Department of Chest Medicine, Taipei Veteran General Hospital, Taipei, Taiwan8School of Medicine, National Yang-Ming University, Taipei, Taiwan
Jong-Seok Lee

Department of Haematology and Medical Oncology, Seoul National University Bundang Hospital, Bundang, Korea
Jin-Hyoung Kang

Seoul St Mary’s Hospital, Seoul, Korea
K. C. Allen Chan

Department of Chemical Pathology, Chinese University of Hong Kong, Hong Kong
Pablo Perez-Moreno

F. Hoffmann–La Roche Ltd, Basel, Switzerland
Peter Button

Roche Products Pty Ltd, Dee Why, Australia
Myung-Ju Ahn

Division of Haematology-Oncology, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea
Tony Mok

State Key Laboratory of South China, Hong Kong Cancer Institute, Chinese University of Hong Kong, Sha Tin, Hong Kong

Bibliographic Information

Other Title

JAMA Oncology

JAMA Oncology 2 (3), 305-, 2016-03-01

American Medical Association (AMA)

Back to top